Visceral adipose tissue (VAT) is a metabolically active organ, associated with higher risk of malignancies. We evaluated whether VAT is associated with the risk of hepatocellular carcinoma (HCC) in patients presenting with cirrhosis as well as HCC recurrence after liver transplantation (LT). Patients with cirrhosis (n 5 678; 457 male) who were assessed for LT (289 with HCC) were evaluated for body composition analysis. Patients who underwent LT (n 5 247, 168 male) were subsequently evaluated for body composition, and 96 of these patients (78 male) had HCC. VAT, subcutaneous adipose tissues, and total adipose tissues were quantified by computed tomography at the level of the third lumbar vertebra and reported as indexes (cross-sectional area normalized for height [square centimeters per square meter]). At the time of LT assessment, the VAT index (VATI) was higher in male patients with HCC compared to non-HCC patients (75 6 3 versus 60 6 3 cm 2 /m 2 , P 5 0.001). The VATI, subcutaneous adipose tissue index, and total adipose tissue index were higher in male patients with HCC compared to non-HCC patients. By multivariate analysis, male patients with VATI 65 cm 2 /m 2 had a higher risk of HCC (hazard ratio, 1.90; 95% confidence interval, 1.31-2.76; P 5 0.001). In male patients with HCC who underwent LT, a VATI 65 cm 2 /m 2 adjusted for Milan criteria was independently associated with higher risk of HCC recurrence (hazard ratio, 5.34; 95% confidence interval, 1.19-23.97; P 5 0.03). Conclusion: High VATI is an independent risk factor for HCC in male patients with cirrhosis and for recurrence of HCC after LT. (HEPATOLOGY 2018;67:914-923).
Visceral adipose tissue (VAT) is a metabolically active organ, associated with higher risk of malignancies. We evaluated whether VAT is associated with the risk of hepatocellular carcinoma (HCC) in patients presenting with cirrhosis as well as HCC recurrence after liver transplantation (LT). Patients with cirrhosis (n 5 678; 457 male) who were assessed for LT (289 with HCC) were evaluated for body composition analysis. Patients who underwent LT (n 5 247, 168 male) were subsequently evaluated for body composition, and 96 of these patients (78 male) had HCC. VAT, subcutaneous adipose tissues, and total adipose tissues were quantified by computed tomography at the level of the third lumbar vertebra and reported as indexes (cross-sectional area normalized for height [square centimeters per square meter]). At the time of LT assessment, the VAT index (VATI) was higher in male patients with HCC compared to non-HCC patients (75 6 3 versus 60 6 3 cm H epatocellular carcinoma (HCC) is the dominant form of liver cancer, occurring mainly in patients with cirrhosis. (1) Gender differences exist in HCC incidence, with men having greater risk. (2) Obesity, defined by a body mass index (BMI) of at least 30 kg/m 2 , is associated with a significant risk of cancer in epidemiological studies (3, 4) ; however, obesity is a heterogeneous condition with distinct variance in the arrangement of adipose tissue deposition. Accumulation of abdominal adipose tissue, mainly in the visceral compartment, seems to confer the majority of obesity-associated disease risk. (5) Visceral adipose tissue (VAT) is metabolically active, associated with adipokine and proinflammatory cytokine production. VAT has been associated with higher risk of malignancies, mainly colorectal (6, 7) but also breast, (8) (9) (10) esophageal, (11) and prostate (12) cancers. In general, women have a higher amount of body adipose tissue than men, with a greater distribution in the gluteal-femoral region, whereas men have more adipose tissue located in the abdominal region. (13) The application of in vivo imaging techniques, such as computed tomography (CT) and magnetic resonance imaging, has enabled recent advances in understanding the relationship of components of body composition to disease and clinical outcomes. (14) In clinical populations who have CT images available as part of standard care, quantification of muscle and different adipose tissue depots is possible. (15) These techniques have revealed that a high proportion of fat and visceral adiposity can present in people within any category of BMI as well as in populations with high or low amounts of muscle. (16) Currently, there is no systematic evidence linking VAT to HCC risk and recurrence in cirrhosis patients. HCC is the dominant indication for up to 40% of all liver transplants (LTs) performed at most centers worldwide (17) ; therefore, it is imperative to assess the effect of VAT on the incidence and recurrence of HCC. Considering variability in adipose tissue distribution by gender and within each BMI category, (18) (19) (20) the aims of this study were to evaluate if VAT is independently associated with HCC risk in patients with cirrhosis, establish its correlation with BMI, and finally evaluate the potential association with HCC recurrence after LT.
Patients and Methods

STUDY POPULATION
Clinical and demographic characteristics of subjects were collected from the Alberta Liver Transplant database. Adult patients with cirrhosis who had a CT image taken as part of routine assessment for LT at the University of Alberta Hospital between January 2000 and May 2014 were initially reviewed (n 5 927). Patients who did not have cirrhosis, who were retransplanted, or who had multiple organ transplantation (n 5 249) were excluded, for a total of 678 patients for inclusion in the study (Fig. 1) .
ADIPOSE TISSUE EVALUATION
CT scans were performed as standard of care during LT assessment. A transverse CT image at the level of the third lumbar vertebra was selected from each scan. Images were analyzed with SliceOmatic V4.3 software (Tomovision, Montreal, QB, Canada), which enables specific tissue demarcation using reported Hounsfield unit thresholds. (21) The following Hounsfield unit thresholds were used for adipose tissues: -190 to -30 for subcutaneous and intermuscular adipose tissue (22) and -150 to -50 for VAT. (14) Tissue annotation and quantification were performed by an analyst trained in cross-sectional anatomy. Cross-sectional areas (square centimeters) were automatically computed by summing tissue pixels and multiplying by pixel surface area. Cross-sectional areas of adipose tissues were normalized for height (square centimeters per square meter) to give a VAT index (VATI), a subcutaneous adipose tissue (SAT) index (SATI), and a total adipose tissue index (TATI), as reported. 
STATISTICAL ANALYSES
Data are presented as the mean 6 standard error of the mean or frequencies and percentages. Nonparametric variables were compared with the Mann-Whitney test. Prognostic factors for HCC were analyzed by univariable logistic regression analysis. Variables of interest plus variables with a P value <0.1 in univariable analysis were included in a multivariable regression analysis. A receiver-operating characteristics curve was plotted to establish VATI cutoff values associated with HCC. The validity of the model was measured by the area under the curve. Correlation between VATI and BMI was determined by Pearson correlation coefficient (r) analysis. Given the gender-specific nature of HCC and differences in adipose tissue distribution by gender, (25) body composition variables were compared between patients with and without HCC, in both men and women. Patients with HCC who underwent LT had screening for HCC recurrence with liver ultrasound, CT, or magnetic resonance imaging and alpha-fetoprotein determination every 6 months. Main selection criteria for LT in HCC, including Milan criteria, (26) University of California San Francisco (UCSF) criteria, (27) and total tumor volume (TTV) (28) were analyzed. HCC-free survival after LT, defined as the time between LT and HCC recurrence, was calculated using the Kaplan-Meier method; and values were compared using the log-rank (Mantel-Cox) test. Patients were followed from the date of the LT assessment until the date of death, LT, or the last visit. Prognostic factors for HCC recurrence were analyzed with univariable and multivariable Cox regression analyses.
Results
DEMOGRAPHIC AND CLINICAL FEATURES OF PATIENTS EVALUATED
Of the 678 patients evaluated for LT, 457 were male (67%), with a mean age of 57 6 1 years (median, 57; range, 21-76; Table 1 ). Cirrhosis was attributed to 
FEATURES ASSOCIATED WITH HCC AT LT ASSESSMENT
Patients with HCC were older (58 6 1 versus 56 6 1 years, P < 0.001) and more frequently male (78 versus 60%, P < 0.001) than patients without HCC (Table 1) . Patients with HCC had a higher frequency of nonalcoholic steatohepatitis cirrhosis and lower frequencies of cirrhosis due to alcohol and autoimmune liver diseases compared to non-HCC patients ( Table 1 ). Patients with HCC had lower creatinine, bilirubin, international normalized ratio, and Model for End-Stage Liver Disease (MELD) score than non-HCC patients (Table 1) .
ABDOMINAL ADIPOSE DISTRIBUTION ACCORDING TO HCC AND GENDER
There was no difference in BMI between patients with and without HCC ( Table 1) . Male patients with HCC had higher VATI (75 6 3 versus 60 6 3 cm Table 1 ). The correlation between VATI and BMI in male patients was weak (r 5 0.42, P < 0.001; Fig. 3 ).
There was no difference in VATI, SATI, and TATI between female patients with and without HCC (Table 1) . Therefore, subsequent analysis of the Table 2 ). In order to rule out the possibility that the association between visceral obesity and HCC was driven by nonalcoholic fatty liver disease, a subanalysis was conducted in 368 patients with cirrhosis but without nonalcoholic fatty liver disease. VATI was associated with increased risk for HCC as a dimensional variable (RR, 1.01; 95% CI 1.00-1.01; P 5 0.002) and as a dichotomous variable (RR, 2.21; 95% CI, 1.45-3.38; P < 0.001).
Male patients with VATI 65 cm 2 /m 2 were older; had lower creatinine, international normalized ratio, bilirubin, and MELD; and had higher BMI, total fat, and subcutaneous fat compared to patients with VATI <65 cm 2 /m 2 ( Table 3) .
ASSOCIATION OF VAT WITH HCC RECURRENCE AFTER LT
After being evaluated for LT, 247 patients (81% male) underwent LT. Of these, 96 patients had HCC, including 9 patients (9%) who had incidental HCC, with the majority (81%) being male. Therefore, features associated with HCC recurrence after LT were solely investigated in male patients (n 5 78) ( Table 4) . Fifty-six patients (72%) were within Milan criteria, 62 (80%) were within UCSF criteria, and 76 (97%) had a TTV <115 cm 3 . Male patients with HCC who underwent LT had a higher VATI at the time of LT assessment compared to non-HCC patients (82 6 6 versus 57 6 5 cm 2 /m 2 , P 5 0.002). Fourteen male patients (18%) had HCC recurrence after LT. The characteristics of male patients with HCC recurrence are shown in Table 4 . Patients with HCC recurrence had higher VATI compared with patients who did not have HCC recurrence (119 6 14 versus 74 6 6 cm 2 /m 2 , P 5 0.002). The area under the curve for HCC recurrence was 0.79 (95% CI, 0.67-0.92; P < 0.001). HCC-free survival was lower in patients with VATI 65 cm 
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(median HCC-free survival, 102 6 11 versus 127 6 7 months, P 5 0.02; Fig. 4 ). Table 5 shows the results corresponding to Cox regression analysis. VATI analyzed as a dimensional variable (hazard ratio, 1.02; 95% CI 1.01-1.03; P 5 0.001) and as a dichotomous variable (VATI 65 cm 2 /m 2 ; hazard ratio, 5.17; 95% CI 1.15-23.21; P 5 0.03) was associated with higher risk of HCC recurrence.
In the multivariate analysis, VATI was analyzed as a dimensional variable (model 1) and as a dichotomous variable (model 2) with the different staging criteria pre-LT such as Milan, UCSF, and TTV 115 cm 3 . VATI was independently associated with higher risk of HCC recurrence (Table 5) .
Lastly, we analyzed the explant features, including the explant stage (Milan, UCSF, TTV 115 cm 3 ) and the presence of microvascular invasion; and VATI as a dimensional variable (model 1) was significantly associated with higher risk of HCC recurrence ( increased the risk of HCC recurrence nearly 5-fold. This study reveals that high VATI is associated with higher recurrence rate of HCC, independent of other well-established criteria for HCC recurrence, such as Milan criteria and TTV. (26, 27, 29) Therefore, we believe VATI should be considered as a risk factor for HCC recurrence after LT in male patients.
LT is the most effective treatment for patients with early nonresectable HCC; however, similar to our results, approximately 15% of patients experience a post-LT recurrence, and candidate selection appears to be the most effective action for its prevention. (30, 31) In patients with cirrhosis, there is a significant gender disparity in HCC incidence, with a solid predominance for men regardless of geographic area, etiologic factor, and ethnicity. (32) Similarly, in our study a high VATI was associated with higher risk of HCC before and after LT in male patients.
Our results also confirm that BMI is not a good indicator of adiposity in this population. (19, 20, 33) Therefore, there is a need to understand the role of VAT, rather than just BMI, in the prognosis of HCC in cirrhosis. Our results extend the findings of previous work in patients with nonalcoholic steatohepatitis reporting that VAT constitutes an independent risk factor of HCC recurrence after curative treatment (34) and VAT, sarcopenia, and intramuscular fat deposition independently predict mortality in patients with HCC. (35) Interestingly, of the 96 patients with HCC who received LT, 24 would be considered obese by conventional criteria, whereas 31 patients with BMI <30 had VATI >65 cm 2 /m 2 . Therefore, a high VATI is not exclusively present in obese patients classified according to BMI and constitutes an occult condition that can present in patients with cirrhosis who are within the typical range of BMI. This study emphasized that individual variability in adiposity, especially visceral adiposity, (36, 37) exists within each BMI category. (21, 22) Furthermore, measurement of VAT in cirrhosis is independent of the fluid retention which plagues accurate measurement of body weight and BMI in patients with cirrhosis. Evaluating VAT in patients assessed for LT seems attractive as a CT scan is generally conducted during standard care to screen patients with cirrhosis for potential HCC and as the second-line evaluation of the anatomy of the hepatic vessels and, hence, is a feasible way to determine the VATI.
The association between visceral adiposity and HCC needs to be investigated in larger studies with a greater number of female patients. Potential explanations for the association between visceral obesity and HCC have not been identified. Our study confirms that adipose tissue distribution differs by gender, with women having more subcutaneous adiposity and men having more VAT, both at LT assessment and at the time of LT. It has been shown that estrogen favors fat deposition in subcutaneous compared to visceral depots. (38, 39) Estrogen replacement therapy decreases the risk of HCC as well as improves survival in patients with HCC. (40) Therefore, the lack of association between VATI and HCC in female patients might be related to the effect of estrogen on body fat distribution by prioritizing subcutaneous over visceral accumulation in female patients.
VAT and SAT differ in their metabolic activity, anatomic location, adipokine secretion, and lipolytic activity. (41) (42) (43) VAT is more metabolically active and sensitive to lipolytic stimuli. (43, 44) VAT has been reported to secrete more inflammatory cytokines, such as tumor necrosis factor alpha, (45) interleukin-6, (45) and other adipokines, (46) (47) (48) whereas leptin is more highly secreted by SAT, which exerts metabolic advantages on insulin, glucose, and lipid metabolism. (49) Moreover, adipokines from VAT can be delivered through the portal system directly to the liver, where they promote liver inflammation and might induce or support carcinogenesis. Ex vivo studies have demonstrated that VAT releases a larger amount of interleukin-6 and plasminogen activator 1 compared with SAT. (47, 50) The chronic inflammatory state associated with higher deposition of adipose tissue in the visceral region might favor neoplastic development and explain . The 120-month probability of HCC survival was 63% and 90%, respectively (P 5 0.02, log-rank test). the higher risk for HCC before and after LT. Additionally, VAT is associated with insulin resistance, which might influence the risk of HCC. Patients evaluated for LT who had diabetes had a higher VATI compared to nondiabetic patients.
Our study is retrospective in nature, limiting assessment of other variables to enable interpretation of results and potential assignment of causation. Prospective studies that include markers of inflammation or insulin resistance will enhance our understanding of the pathogenesis of HCC in cirrhosis. Despite difficulty acquiring optimal ultrasound images in patients with high amounts of VAT, tighter screening for HCC in those patients might help to reduce the negative impact of VAT on HCC; however, further investigation is required. Potential strategies such as mammalian target of rapamycin inhibitors (sirolimus/ everolimus) (51) could be implemented to reduce HCC recurrence in those patients with a high amount of VAT. Considering the retrospective nature of this study, a significant number of patients were not eligible for inclusion as no CT scans could be retrieved for these patients. However, we briefly analyzed patients included and excluded from this study, and we did not *Milan criteria, UCSF criteria, and TTV <115 cm 3 were not included in the same model, to avoid collinearity. find significant differences in relation to age, gender, and HCC frequency between these two groups.
In conclusion, CT measurement enables specific quantification of VAT, which is not reflected by BMI. A high amount of VAT is an independent risk factor for HCC in male patients with cirrhosis. Although higher levels of VAT increased the risk of HCC recurrence after LT, the results need to be confirmed in a larger population of patients with cirrhosis.
